In vivo localization of a bispecific antibody which targets human T lymphocytes to lyse human colon cancer cells.
A bispecific MAb was derived from the fusion of a hybridoma producing MAb CD3 with a hybridoma producing MAb L-DI (which is directed against a 41-kDa glycoprotein expressed in most gastro-intestinal and pancreatic carcinomas). Bispecific antibody molecules were isolated from parental antibody molecules by the use of hydroxylapatite-HPLC and shown to target human cytolytic T lymphocytes, irrespective of their original specificity, to specifically lyse human colon carcinoma cells. Localization studies in vivo using nude mice bearing human colon carcinoma xenografts showed significant accumulation of the HPLC-purified 125I-labelled bispecific antibodies into the tumor compared to 131I-labelled control CD3 antibody.
Barr
I G
IG
Ludwig Institute for Cancer Research, Lausanne Branch, Basel, Switzerland.
Miescher
S
S
von Fliedner
V
V
Buchegger
F
F
Barras
C
C
Lanzavecchia
A
A
Mach
J P
JP
Carrel
S
S
D000818:Animals; D000912:Antibodies, Neoplasm / Q000032:analysis* / Q000096:biosynthesis / Q000276:immunology; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003110:Colonic Neoplasms / Q000276:immunology*; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D000912:Antibodies, Neoplasm